DNA-based immune enhancers

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 2, 2000, Pages 214-221

  Krieg, Arthur M ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

Adjuvant; Antigen; CpG motif; Vaccine

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; VACCINE;

ANIMAL CELL; B LYMPHOCYTE; CELL PROLIFERATION; CPG ISLAND; DRUG EFFECT; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0033998633     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Krieg AM, Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta (1999) 93321:1-10.
2. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL, Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc NatlAcad Sci USA (1998) 95:12631-12636.
3. Krieg AM, Yi A-K, Maison S, Waldschmidt TJ. Bishop GA, Teasdale R, Koretzky G, Klinman DM: CpG motifs In bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
4. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE, Activation of human B-cells by phosphorothioate oligodeoxynucleotides. J Clin Invest (1996) 98:1119-1129.
5. Manzel L, MacFartane DE, Lack of immune Stimulation by immobilized CpG-oligodeoxynucleotide. Antisense Nucleic Acid Drug Dev (1999) 9:459-464.
6. Yi A-K, Tuetken R, Redford T, Waldschmidt TJ, Kirsch J, Krieg AM, CpG motifs in bacterial DNA activates leukocytes through the pH-dependent generation of reactive oxygen species. Jlmmunol (1998) 160:4755-4761.
7. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H, CpG-DNAspecific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 17:6230-6240.
8. MacFartane DE, Manzel L, Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. Jlmmunol (1998) 160:1122-1131.
9. Krieg AM, Hartmann G, Yi A-K, Mechanisms of action of CpG DNA. Curr Top Microbiol Immunol (1999) 247:1-21.
10. Strekowski L, Zegrocka O, Henary M, Say M, Mokrosz MJ, Kotecka BM, Manzel L, MacFariane DE, Structure-activity relationship analysis of substituted 4-quinolinamines, antagonists of immunostimulatory CpG-oligodeoxynucleotides. Bioorg Med Chem Lett (1999) 9:1819-1824.
11. Yi A-K, Krieg AM, Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J /mmu/70/(1998) 161:4493-4497.
12. Sester DP, Beasley SJ, Sweet MJ, Fowles LF, Cronau SL, Stacey KJ, Hume DA, Bacterial/CpG DNA down-modulates colony stimulating factor-1 receptor surface expression on murine bone marrow-derived macrophages with concomitant growth arrest and factor-independent survival. Jlmmunol(1999) 163:6541-6550.
13. Sweet MJ, Stacey KJ, Kakuda DK, Markovich D, Hume DA, IFN-y primes macrophage responses to bacterial DNA. J Interferon Cytokine Res (1998) 18:263-271.
14. Cowdery JS, Boerth NJ, Norian LA, Myung PS, Koretzky GA, Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharide. J Immunol (1999)162:6770-6775.
15. Yi A-K, Chang M, Peckham DW, Krieg AM, Ashman RF, CpG oligodeoxyribonucleotides rescue mature spleen B-ceils from spontaneous apoptosis and promote cell cycle entry. J/mmuno/(1998) 160:5898-5906.
16. Yi A-K, Krieg AM, CpG DNA rescue from anti-lgM-induced WEHI-231 B lymphoma apoptosis via modulation of iKBa and K-B and sustained activation of nuclear factor-icB/cRel. J/mmuno/(1998) 160:1240-1245.
17. Hartmann G, Krieg AM, Mechanism and function of a newly identified CpG DNA motif in human primary B-cells. J Immunol (2000) 164:944-952.
18. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM, Delineation of a CpG phosphorothioate oligonucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 164:1617-1624.
19. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC, Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 161:3042-3049.
20. Hartmann G, Krieg AM, CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther (1999) 6:893-903.
21. Hartmann G, Weiner GJ, Krieg AM, CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc NatlAcad Sci USA (1999) 96:9305-9310.
22. Chace JH, Hooker NA, Mildenstein KL, Krieg AM, Cowdery JS, Bacterial DNA-lnduced NK ceil IFN-y production Is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol VS97) 84:185-193.
23. Iho S, Yamamoto T, Takahashi T, Yamamoto S, Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T-cells to induce IFN-y production in vitro. J Immunol (1999) 163:3642-3652.
24. Sun S, Zhang X, Tough DF, Sprent J, Type I interferonmediated stimulation of T-cells by CpG DNA. J Exp Med (1998)188:2335-2342.
25. Davis HL, Weeranta R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, CpG DNA is a potent adjuvant in mice immunized with recombinant hepatitis B surface antigen. J /mmuno/(1998) 160:870-876.
26. Barry MA, Genetic immunization: Applying recombinant DNA technology in the immune system to develop new vaccines. Curr Opin Drug Discovery Dev (1999) 2:118-128.
27. Biswas S, Ashok MS, Reddy GS, Srinivasan VA, Rangarajan PN, Evaluation of the protective efficacy of rabies DNA vaccine in mice using an intracerebral challenge model. Curr Sci (1999) 76:1012-1016.
28. Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A, Gene gun DNA vaccination with Revindependent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vacc/ne(1999) 17:2166-2175.
29. Grifantini R, Finco O, Bertonni E, Draghi M, Del Giudice G, Kocken C, Thomas A, Abrignani S, Grandi G, Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmld. Eur J Immunol (1998) 28:1225-1232.
30. Krieg AM, Yi A-K, Schorr J, Davis HL, The role of CpG dinucleotides in DNA vaccines. Trends Microbiol (1998) 6:23-27.
31. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B, DNA vaccination: Transfection and activation of dendritic cells as key events for Immunity. J Exp Med (1999)189:169-178.
32. Dow SW, Fradkin LG, Uggitt DH, Willson AP, Heath TD, Potter TA, Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. Jlmmunol (1999) 163:1552-1561.
33. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, Makiguchi N, Suganuma T, Antitumor activity of deoxyribonucleic acid fraction from mycobacterium bovis GCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst (1984) 72:955-962.
34. Carpentier AF, Chen L, Maitonti F, Delattre J-Y, Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res (1999) 59:5429-5432.
35. Krieg AM, Love-Homan L, Yi A-K, Harty JT, CpG DNA induces sustained IL-12 expression In vivo and resistance to Listeria monocytogenes challenge. J Immunol (1998) 161:2428-2434.
36. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM, Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol (1999) 162:2291-2298.
37. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K, CpG Oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J/rtifnuno/(1998) 160:3627-3630.
38. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC, Immunostimulatory Oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-y-dependent mechanisms. Proc Natl Acad Sci USA (1999)96:6970-6975.
39. Oxenius A, Martinic MM, Hengartner H, Klenerman P, CpGcontaining oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with Tcell peptide vaccines. J Wro/(1999) 73:4120-4126.
40. Stacey KJ, Blackwell JM, Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun (1999) 67:3719-3726.
41. Klinman DM, Verthelyi D, Takeshita F, Ishii KJ, Immune recognition of foreign DMA: A cure for bioterrorism. Immunity;(1999) 11:123-129.
42. Klinman DM, Conover J, Coban C, Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun (1999) 67:5658-5663.
43. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV, CpG oligodeoxynucleotides act as adjuvants that switch on Thelper 1 (Th1 ) immunity. J Exp Med (1997) 186:1623-1631.
44. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K, CpG-containing synthetic oligonucleotides promote B and cytotoxic T-cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol (1997) 27:2340-2344.
45. Schirmbeck R, Melber K, Reimann J, Adjuvants that enhance priming of cytotoxic T-cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen. Int Immunol (1999) 11:1093-1102.
46. Chelvarajan RL, Raithatha R, Venkataraman C, Kaul R, Han SS, Robertson DA, Bondada S, CpG oligodeoxynucleotides overcome the unresponslveness of neonatal B-cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficoll. Eur J Immunol (1999) 29:2808-2818.
47. Weiner GJ, Liu H-M, Wooldridge JE, Dahle CE, Krieg AM, Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Nail Acad Sci USA (1997) 94:10833-10837.
48. Liu H-M, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ, Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies Involving granulocyte-macrophage colony-stimulating factor. Stood (1998) 92:3730-3736.
49. Sun S, Cai Z, Langlade-Demoyen P, Kosaka H, Brunmark A, Jackson MR, Peterson PA, Sprent J, Dual function of Drosophila cells as APCs for naive CD8+ T-cells: Implications for tumor immunotherapy. Immunity (1996) 4:555-564.
50. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM, CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine (1998) 16:12161224.
51. McCluskie MJ, Davis HL, CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol (1998) 161:4463-4466.
52. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL, CpG DNA Is an effective oral adjuvant to piotein antigens in mice. Vaccine (2000) in press.
53. Erb KJ: Atopic disorders: A default pathway in the absence of infection? Immunol Today (1999) 20:317-322.
54. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL, CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA (1998) 95:15553-15558.
55. Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert P-H, Krieg AM, Siegrist C-A, CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol (1999) 162:1611 -1617.
56. Jones TR, Obaldia N, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL, Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccines (1999) 17:3065-3071.
57. Gramzinski RA, Millan CL, Obaldia N, Huffman SL, Davis HL, Immune response to a hepatitis B DNA vaccine in Aotus monkeys: A comparison of vaccine formulation, route, and method of administration. Mol Med (1998) 4:109-118.
58. Davis HL, Suparto I, Weeratna R, Iskandriati D, Krieg AM, Sajuthi D, Vaccination of orangutans at risk for hepatitis B infection: Hyporesponsiveness to hepatitis B surface antigen overcome by CpG DNA. Vaccine (2000) in press.
59. Kline JN, Effects of CpG PNA on Th1/Th2 balance in asthma. Curr Top in Microbiol and Immunol (1999) 247:211225.
60. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thome PS, Krieg AM, Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol (1998) 160:2555-2559.
61. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen M-D, Malek S, Van Uden J, Martin-Orozco E, Gelfand EW, Raz E, Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol (1998) 161:70547062.
62. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM, Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J /mmuno/(1999) 162:6284-6293.
63. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR, CpG oligodeoxynucleotides do not require Th1 cytokines to prevent airway eosinophilia in a murine model of asthma. J Allergy Clin Immunol (1999) 104:12581264.
64. Chiaramonte MG, Hesse M, Cheever AW, Wynn TA, CpG oligonucleotides can prophylactically immunize against Th2mediated schistomsome egg-induced pathology by an IL-12independent mechanism. J Immunol (2000) 164:973-985. • These manuscripts, references [59-64], all demonstrate the remarkable efficacy of CpG DMA in preventing and treating allergic airways disease. Together, the manuscripts show that CpG DNA alone or in combination with antigen is highly effective at blocking allergic Th2 immune responses.
65. Schwarte DA, Quinn TJ, Thome PS, Sayeed S, Yi A-K, Krieg AM, CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest (1997) 100:68-73.
66. Schwarte DA, Wohlford-Lenane CL, Quinn TJ, Krieg AM, Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol (1999) 163:224-231.
67. Cowdery JS, Chace JH, Yi A-K, Krieg AM, Bacterial DNA induces NK cells to produce IFN-y in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 156:4570-4575.
68. Sparwasser T, Miethke T, Lipford G, Borschert K, Hacker H, Heet K, Wagner H, Bacterial DNA causes septic shock. Nature (1997) 386:336-337.
69. Krieg AM: CpG DNA: A pathogenic factor in systemic lupus erythematosus? J Clin Immunol (1995) 15:284-292.
70. Gilkeson GS, Ruiz P, Pippen AM, Alexander AL, Lefkowith JB, Pisetsky DS, Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J Exp Med(1996) 183:1389-1397.
71. Mor G, Singla M, Steinberg AD, Hoffman SL, Okuda K, Klinman DM: Do DNA vaccines induce autoimmune disease? Hum Gene T/7er(1997) 8:293-300.
72. Segal BM, Klinman DM, Shevach EM, Microbial products induce autoimmune disease by an IL-12-dependent pathway. J Immunol (1997) 158:5087-5090.
73. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM, Chlamydia infections and heart disease linked through antigenic mimicry. Science (1999) 283:1335-1339.
74. Deng G-M, Nilsson I-M, Verdrengh M, Collins LV, Tarkowski A, Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nature Med (1999) 5:702-705.
75. Redford TW, Yi A-K, Ward CT, Krieg AM, Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol (1998) 161:3930-3935.